Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
This site may receive compensation from the provider linked above. Full disclosure.
Nevada residents can now access genuine, pharmaceutical-grade GLP-1 therapy entirely online through GenuinePeptide. Unlike providers who source from unaccredited compounding operations or dispense unverified peptide compounds, GenuinePeptide prescribes only FDA-approved GLP-1 medications — semaglutide, tirzepatide, and liraglutide — dispensed by PCAB-accredited pharmacies with independent batch testing confirming potency, purity, and sterility.
Our board-certified physicians conduct thorough eligibility reviews for Nevada patients, prescribe personalized GLP-1 protocols with precise dose escalation schedules, and provide ongoing telehealth monitoring throughout your treatment. Every medication is delivered to any Nevada address within 2-5 business days with temperature-controlled shipping.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
GLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in .
Three FDA-approved compounds, each dispensed by PCAB-accredited pharmacies with independent batch testing and physician oversight for Nevada patients.
The most established FDA-approved GLP-1 receptor agonist — authentic semaglutide with a 14.9% average weight reduction demonstrated in the STEP 1 trial. Physician-prescribed for eligible Nevada residents and dispensed only by PCAB-accredited pharmacies with batch-level quality verification.
The highest-efficacy FDA-approved GLP-1/GIP dual agonist, achieving up to 22.5% weight reduction in SURMOUNT-1. Genuine tirzepatide prescribed for Nevada patients when clinically appropriate, dispensed by PCAB-accredited pharmacies with independent potency and sterility testing.
An established daily FDA-approved GLP-1 option with over 10 years of real-world safety data. Ideal for Nevada patients who prefer daily dosing or have clinical considerations favoring a daily schedule. Dispensed from PCAB-accredited pharmacies with pharmaceutical-grade quality documentation.
Licensed GLP-1 telehealth care available statewide. Choose your city to start your clinical assessment.
Every GLP-1 prescription for Nevada residents is dispensed exclusively by PCAB-accredited compounding pharmacies. Each batch undergoes independent third-party testing for potency, purity, and sterility — and you receive documentation confirming your medication is pharmaceutical-grade. GenuinePeptide never sources from unaccredited pharmacies, grey-market suppliers, or unregulated peptide vendors.
PCAB (Pharmacy Compounding Accreditation Board) accreditation means a pharmacy has met the highest voluntary standards for sterile compounding in the US — including rigorous quality control processes, staff credentialing, facility standards, and independent batch testing. For Nevada patients, it means your GLP-1 medication was compounded under pharmaceutical-grade conditions with documented quality verification on every lot.
GenuinePeptide prescribes three FDA-approved GLP-1 medications for eligible Nevada residents: semaglutide (the active compound in Ozempic/Wegovy, with 14.9% average weight reduction), tirzepatide (the active compound in Mounjaro/Zepbound, with up to 22.5% weight reduction), and liraglutide (the active compound in Saxenda, a proven daily option). Your physician recommends the most clinically appropriate compound for your individual profile.
Board-certified physicians have undergone specialized training and rigorous board examinations beyond general medical school. For GLP-1 therapy in Nevada, this means your prescription is reviewed by a physician with specific expertise in obesity medicine, metabolic health, contraindication screening, and dose escalation protocols. Physician certification is the clinical safeguard that ensures your genuine GLP-1 medication is prescribed safely and effectively.
Local weight loss and GLP-1 providers serving the Nevada area, based on Google Business listings.
9017 S Pecos Rd %234425, Henderson, NV 89074
(702) 988-9616
5/5 ★ (51 reviews)
Visit website →180 W Huffaker Ln %23306, Reno, NV 89511
(775) 399-6577
4.9/5 ★ (207 reviews)
Visit website →6930 S Cimarron Rd %23220, Las Vegas, NV 89113
(702) 822-7400
4.9/5 ★ (380 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
